Biomarkers increase detection of active smoking and secondhand smoke exposure in critically ill patients*
- 1 January 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 39 (1), 40-45
- https://doi.org/10.1097/ccm.0b013e3181fa4196
Abstract
Objectives: The association between tobacco smoke exposure and critical illness is not well studied, largely because obtaining an accurate smoking history from critically ill patients is difficult. Biomarkers can provide quantitative data on active and secondhand cigarette smoke exposure. We sought to compare cigarette smoke exposure as measured by biomarkers to exposure by self-report in a cohort of critically ill patients and to determine how well biomarkers of cigarette smoke exposure correlate with each other in this population. Design, Setting, and Patients: Serum and urine cotinine and trans-3′-hydroxycotinine, urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and hair and nail nicotine levels were measured in 60 subjects enrolled in an observational cohort of critically ill subjects at a tertiary academic medical center in Tennessee. Smoking history was obtained from patients, their surrogates, or the medical chart. Cigarette smoke exposure as measured by biomarkers was compared to exposure by history. Measurements and Main Results: By smoking history, 29 subjects were identified as smokers, 28 were identified as nonsmokers, and 3 were identified as unknown. The combination of serum cotinine and urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol identified 27 of the 28 nonsmokers by history either as active smokers (n = 6, 21%) or as exposed to secondhand smoke (n = 21, 75%). All biomarker levels were strongly correlated with each other (r = .69–.95, p < .0001). Conclusions: The combination of serum cotinine and urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol identified considerably more active smokers than did smoking history and detected a high prevalence of secondhand smoke exposure in a critically ill population. These markers will be important for future studies investigating the relationship between active smoking and secondhand smoke exposure and critical illness.This publication has 25 references indexed in Scilit:
- Elimination Kinetics of the Tobacco-Specific Biomarker and Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-ButanolCancer Epidemiology, Biomarkers & Prevention, 2009
- Reliability of self reported smoking status by pregnant women for estimating smoking prevalence: a retrospective, cross sectional studyBMJ, 2009
- Prevalence of Smoking Assessed Biochemically in an Urban Public Hospital: A Rationale for Routine Cotinine ScreeningAmerican Journal of Epidemiology, 2009
- Longer term exposure to secondhand smoke and health outcomes in COPD: Impact of urine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanolNicotine & Tobacco Research, 2009
- Acute and Short-term Effects of Secondhand Smoke on Lung Function and Cytokine ProductionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Nicotine Chemistry, Metabolism, Kinetics and BiomarkersPublished by Springer Science and Business Media LLC ,2009
- Nicotine Intake in Cigarette Smokers in England: Distribution and Demographic CorrelatesCancer Epidemiology, Biomarkers & Prevention, 2008
- Subpicogram per Milliliter Determination of the Tobacco-Specific Carcinogen Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol in Human Urine Using Liquid Chromatography−Tandem Mass SpectrometryAnalytical Chemistry, 2008
- Trends in the Exposure of Nonsmokers in the U.S. Population to Secondhand Smoke: 1988–2002Environmental Health Perspectives, 2006
- APACHE IICritical Care Medicine, 1985